Sector News

Takeda spins off cancer assets to incubated startup

November 22, 2017
Life sciences

A team of ex-Takeda scientists has struck out on its own with cancer assets licensed from the drugmaker. The resulting biotech, Chordia Therapeutics, starts life with multiple oncology drugs, lab space at a Takeda site and funding from the Japanese firm and a VC syndicate.

Chordia’s programs include preclinical CDC-like kinase (CLK) inhibitors with applications in cancer and an adult T cell leukemia lymphoma drug. The assets were working their way down Takeda’s pipeline. But with the company rethinking its R&D strategy, a team of six ex-Takeda scientists, including the former head of oncology drug discovery at its Shonan site, has been able to pick up the programs and the means to develop them further.

Takeda is providing support on every front. Chordia has lab space at Takeda’s Shonan site, which is undergoing a transformation into a startup incubator, and funding from its parent company. Kyoto University Innovation Capital, Mitsubishi UFJ Capital and SMBC Venture Capital contributed to Chordia’s series A, too.

Chordia has also enlisted the support of Kyoto University’s Seishi Ogawa, who will use his work on splicing factor mutations in cancer to help the startup develop CLK inhibitors that kill tumor cells.

Takeda referred briefly to Chordia in its second-quarter results earlier this month, naming it as one of three companies founded through its entrepreneurship venture program. The drugmaker unveiled the others, discovery services shops ChromaJean and Seedsupply, in press releases earlier this year.

The emergence of the three startups comes shortly after Takeda spun out another drug discovery service shop, Axcelead. Each company is the result of Takeda’s decision to turn its research center in Shonan, Japan, into a startup incubator. The site is also hosting and supporting other Takeda spinoffs and joint ventures, such as Cardurion, Scohia Pharma and T-Cira.

Takeda’s burst of startup creation activity took place on either side of its 2016 decision to restructure its R&D operation. The headline actions in the restructuring were the refocusing of the operation around four franchises—oncology, gastroenterology, the central nervous system and vaccines—and two geographies, the U.S. and Japan. But the rethink has also led Takeda to conclude some assets are best served by startups, even if they fall within its areas of focus.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend